BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 27875302)

  • 1. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
    Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK
    J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
    He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
    Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. USP19 deubiquitinates EWS-FLI1 to regulate Ewing sarcoma growth.
    Gierisch ME; Pedot G; Walser F; Lopez-Garcia LA; Jaaks P; Niggli FK; Schäfer BW
    Sci Rep; 2019 Jan; 9(1):951. PubMed ID: 30700749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma.
    Jiménez JA; Apfelbaum AA; Hawkins AG; Svoboda LK; Kumar A; Ruiz RO; Garcia AX; Haarer E; Nwosu ZC; Bradin J; Purohit T; Chen D; Cierpicki T; Grembecka J; Lyssiotis CA; Lawlor ER
    Mol Cancer Res; 2021 Jul; 19(7):1182-1195. PubMed ID: 33741715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.
    Niedan S; Kauer M; Aryee DN; Kofler R; Schwentner R; Meier A; Pötschger U; Kontny U; Kovar H
    Oncogene; 2014 Jul; 33(30):3927-38. PubMed ID: 23995784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors.
    Li Y; Li X; Fan G; Fukushi J; Matsumoto Y; Iwamoto Y; Zhu Y
    Cancer Lett; 2012 Jul; 320(1):14-22. PubMed ID: 22266186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis.
    Sen N; Cross AM; Lorenzi PL; Khan J; Gryder BE; Kim S; Caplen NJ
    Mol Carcinog; 2018 Oct; 57(10):1342-1357. PubMed ID: 29873416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
    Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
    Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
    Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
    Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ablation of EWS-FLI1 by USP9X inhibition suppresses cancer cell growth in Ewing sarcoma.
    Wang S; Huo X; Yang Y; Mo Y; Kollipara RK; Kittler R
    Cancer Lett; 2023 Jan; 552():215984. PubMed ID: 36330954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.
    Franzetti GA; Laud-Duval K; Bellanger D; Stern MH; Sastre-Garau X; Delattre O
    Oncogene; 2013 Aug; 32(33):3915-21. PubMed ID: 22986530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis.
    Stoll G; Surdez D; Tirode F; Laud K; Barillot E; Zinovyev A; Delattre O
    Nucleic Acids Res; 2013 Oct; 41(19):8853-71. PubMed ID: 23935076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
    Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
    PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.
    Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T
    Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.
    Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF
    Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors.
    Mendiola M; Carrillo J; García E; Lalli E; Hernández T; de Alava E; Tirode F; Delattre O; García-Miguel P; López-Barea F; Pestaña A; Alonso J
    Int J Cancer; 2006 Mar; 118(6):1381-9. PubMed ID: 16206264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ewing sarcoma EWS protein regulates midzone formation by recruiting Aurora B kinase to the midzone.
    Park H; Turkalo TK; Nelson K; Folmsbee SS; Robb C; Roper B; Azuma M
    Cell Cycle; 2014; 13(15):2391-9. PubMed ID: 25483190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of HDACs reduces Ewing sarcoma tumor growth through EWS-FLI1 protein destabilization.
    Pedot G; Marques JG; Ambühl PP; Wachtel M; Kasper S; Ngo QA; Niggli FK; Schäfer BW
    Neoplasia; 2022 May; 27():100784. PubMed ID: 35366465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.